Literature DB >> 1545592

Distribution of mesalamine enemas in patients with active distal ulcerative colitis.

N J Chapman1, M L Brown, S F Phillips, W J Tremaine, K W Schroeder, M K Dewanjee, A R Zinsmeister.   

Abstract

Mesalamine (5-aminosalicylic acid), a topically administered anti-inflammatory agent, is effective treatment by enema for distal ulcerative colitis; it lacks many of the side effects of orally administered sulfasalazine. In this study, we determined the colonic distribution of a 60-ml mesalamine enema in eight patients (five women and three men, 18 to 48 years old) with active distal ulcerative colitis that ranged from 12 to 40 cm proximal to the anal verge. On 3 consecutive days, each patient self-administered a 4-g (60-ml) 5-aminosalicylic acid enema that contained 3.7 MBq of [99mTc]technetium-sulfur colloid. Anterior and posterior images were obtained at 0, 30, 60, 120, and 240 minutes. During the 4-hour study period, all patients retained the enemas. The enemas spread to the sigmoid region in 24 of 24 studies, to the splenic flexure region in 22 of 24, and to the transverse colon in 1 of 24. Most of the enema was retained in the sigmoid colon. Therefore, we conclude that a 60-ml enema, when administered as recommended clinically, routinely flows retrograde as far as the splenic flexure but rarely spreads beyond this point. These results support the use of intrarectally administered 5-aminosalicylic acid for segmental colitis of the descending colon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1545592     DOI: 10.1016/s0025-6196(12)60100-1

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  7 in total

1.  Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.

Authors:  J K Marshall; E J Irvine
Journal:  Gut       Date:  1997-06       Impact factor: 23.059

2.  A Comparative Pre-Phase I Study of the Impact of Gel Vehicle Volume on Distal Colon Distribution, User Experience, and Acceptability.

Authors:  Ethel D Weld; Hiwot Hiruy; Kate Morrow Guthrie; Joseph L Fava; Sara E Vargas; Karen Buckheit; Robert Buckheit; Hans Spiegel; Jennifer Breakey; Edward J Fuchs; Craig W Hendrix
Journal:  AIDS Res Hum Retroviruses       Date:  2016-12-13       Impact factor: 2.205

3.  Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.

Authors:  Shubha Priyamvada; Anoop Kumar; Seema Saksena; Hayat Onyuksel
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307

4.  Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.

Authors:  Gary R Lichtenstein; Stephen B Hanauer; William J Sandborn
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-03

5.  Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.

Authors:  Brian P Bosworth; William J Sandborn; David T Rubin; Joseph R Harper
Journal:  Inflamm Bowel Dis       Date:  2016-08       Impact factor: 5.325

6.  Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.

Authors:  David T Beattie; M Teresa Pulido-Rios; Fei Shen; Melissa Ho; Eva Situ; Pam R Tsuruda; Patrick Brassil; Melanie Kleinschek; Sharath Hegde
Journal:  J Inflamm (Lond)       Date:  2017-12-06       Impact factor: 4.981

7.  Butyrate-induced transcriptional changes in human colonic mucosa.

Authors:  Steven A L W Vanhoutvin; Freddy J Troost; Henrike M Hamer; Patrick J Lindsey; Ger H Koek; Daisy M A E Jonkers; Andrea Kodde; Koen Venema; Robert J M Brummer
Journal:  PLoS One       Date:  2009-08-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.